The proof-of-concept study demonstrated that the CRISPR/Cas9 genome editing system can be used to correct a mutation in the CFTR gene in cultured intestinal stem cells of cystic fibrosis patients, and the corrected allele is expressed and fully functional as measured in clonally expanded organoids [13]. Here, CFTR is linked to cystic fibrosis.